MicroRNA-384 is lowly expressed in human prostate cancer cells and has anti-tumor functions by acting on HOXB7 - 17/05/19
pages | 7 |
Iconographies | 6 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | MiR-384 was lowly expressed in CAP cell lines. |
• | MiR-384 overexpression inhibited CAP in vitro proliferation and migration. |
• | MiR-384 overexpression inhibited CAP in vivo tumorigenesis. |
• | HOXB7 was directly targeted by miR-384 in CAP cells. |
• | HOXB7 upregulation reversed the anti-cancer effect of miR-384 in CAP cells. |
Abstract |
Objectives |
In this work, we evaluated the expression of microRNA-384 (miR-384) in human prostate cancer (CAP) cells and its regulatory role on CAP in vitro and in vivo functions.
Methods |
In CAP cell lines, miR-384 expression was evaluated by qRT-PCR. In LNCaP and VCaP cells, lentiviral infection was done to overexpress miR-384. The regulatory effects of miR-384 overexpression on CAP in vitro proliferation and migration, and in vivo tumorigenesis, were evaluated, respectively. The targeting of miR-384 on Homeobox b7 gene (HOXB7), was evaluated by dual-luciferase reporter assay and qRT-PCR. In addition, HOXB7 was upregulated in miR-384-overexpressed CAP cells to evaluate the correlated role of HOXB7 in miR-384-mediated CAP proliferation and migration in vitro.
Results |
MiR-384 was lowly expressed in CAP cell lines. Lentiviral infection induced miR-384 overexpression inhibited CAP in vitro proliferation and migration, and in vivo tumorigenesis. HOXB7 was directly targeted by miR-384 in CAP cells. In miR-384-overexpressed CAP cells, HOXB7 upregulation reversed the effect of miR-384 by promoting CAP in vitro proliferation and migration.
Conclusion |
MiR-384 was downregulated in CAP cells. MiR-384 overexpression suppressed CAP in vitro and in vivo development, possibly via acting through its downstream target gene of HOXB7.
Le texte complet de cet article est disponible en PDF.Keywords : CAP, miR-384, HOXB7, Cancer function, Proliferation, Migration, Tumorigenesis
Plan
Vol 114
Article 108822- juin 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?